Teladoc Health (NYSE:TDOC) Research Coverage Started at The Goldman Sachs Group

The Goldman Sachs Group assumed coverage on shares of Teladoc Health (NYSE:TDOC) in a research note published on Friday morning, Marketbeat Ratings reports. The firm issued a buy rating and a $14.00 target price on the health services provider’s stock.

A number of other equities analysts have also recently issued reports on TDOC. Deutsche Bank Aktiengesellschaft raised their target price on Teladoc Health from $10.00 to $12.00 and gave the stock a “hold” rating in a report on Friday, November 1st. Truist Financial decreased their price objective on shares of Teladoc Health from $15.00 to $10.00 and set a “hold” rating for the company in a report on Friday, August 2nd. DA Davidson cut their target price on shares of Teladoc Health from $12.00 to $8.00 and set a “neutral” rating on the stock in a report on Thursday, August 1st. JPMorgan Chase & Co. decreased their price target on shares of Teladoc Health from $16.00 to $9.00 and set a “neutral” rating for the company in a report on Monday, August 26th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $10.00 target price on shares of Teladoc Health in a report on Tuesday, August 20th. Fourteen equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $12.08.

Teladoc Health Trading Up 2.8 %

TDOC opened at $9.21 on Friday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.73 and a quick ratio of 1.69. The company has a market cap of $1.59 billion, a price-to-earnings ratio of -1.60 and a beta of 0.90. The firm has a 50 day simple moving average of $8.89 and a 200 day simple moving average of $9.36. Teladoc Health has a fifty-two week low of $6.76 and a fifty-two week high of $22.54.

Teladoc Health (NYSE:TDOC) last released its earnings results on Wednesday, October 30th. The health services provider reported ($0.19) EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.10. Teladoc Health had a negative net margin of 37.91% and a negative return on equity of 10.06%. The firm had revenue of $640.51 million during the quarter, compared to analyst estimates of $630.50 million. On average, sell-side analysts anticipate that Teladoc Health will post -1.17 earnings per share for the current year.

Insider Activity at Teladoc Health

In other news, Director Thomas Mckinley bought 4,000 shares of the stock in a transaction that occurred on Thursday, September 12th. The shares were acquired at an average cost of $7.69 per share, for a total transaction of $30,760.00. Following the completion of the acquisition, the director now owns 39,077 shares in the company, valued at approximately $300,502.13. This represents a 11.40 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, COO Michael Willem Waters sold 4,218 shares of the stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $7.16, for a total transaction of $30,200.88. Following the completion of the sale, the chief operating officer now owns 78,309 shares of the company’s stock, valued at approximately $560,692.44. This represents a 5.11 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 20,051 shares of company stock valued at $143,565. 0.95% of the stock is owned by insiders.

Hedge Funds Weigh In On Teladoc Health

Institutional investors have recently bought and sold shares of the business. Rubric Capital Management LP bought a new position in shares of Teladoc Health during the 2nd quarter worth approximately $45,267,000. Point72 Asset Management L.P. boosted its position in Teladoc Health by 221.9% during the second quarter. Point72 Asset Management L.P. now owns 5,303,123 shares of the health services provider’s stock worth $51,865,000 after purchasing an additional 3,655,436 shares during the period. Clearline Capital LP increased its holdings in shares of Teladoc Health by 395.6% in the second quarter. Clearline Capital LP now owns 4,364,201 shares of the health services provider’s stock valued at $42,682,000 after purchasing an additional 3,483,665 shares during the last quarter. Assenagon Asset Management S.A. bought a new position in shares of Teladoc Health in the third quarter valued at about $15,801,000. Finally, Maple Rock Capital Partners Inc. acquired a new stake in shares of Teladoc Health during the 3rd quarter worth about $11,291,000. Institutional investors and hedge funds own 76.82% of the company’s stock.

Teladoc Health Company Profile

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.